Results 261 to 270 of about 1,055,467 (319)

In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated <i>Listeria monocytogenes</i> Vaccine Expressing GUCY2C. [PDF]

Vaccines (Basel)
Singh J, Johar T, Scully V, Waldman SA, Bashir B, Snook AE.   +5 more
europepmc   +1 more source

AI-programmable therapeutics via metagenomic foundation models for rare phage-mediated autoimmune modulations: early translational risks and benefits. [PDF]

Ann Med Surg (Lond)
Habib E, Urooj I, Barry HD, Awais M, Kumari M, Hajj F.   +5 more
europepmc   +1 more source

Exosome-based therapeutics: emerging extracellular vesicle platforms for targeted delivery in inherited retinal dystrophies and beyond. [PDF]

Ann Med Surg (Lond)
Khan SA, Ali T, Hameed A, Tahir A, Qamar MA.   +4 more
europepmc   +1 more source

The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena. [PDF]

Mol Ther Nucleic Acids
Giangrande PH.
europepmc   +1 more source

Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.

J Clin Endocrinol Metab
Miller JL, Bridges N, Felner EI, Salehi P, Yanovski JA, Stevenson DA, Mejia-Corletto J, Shaikh MG, Abuzzahab MJ, Fleischman A, Kimonis V, Shoemaker AH, Holland A, Bird LM, Obrynba KS, Lah M, Littlejohn E, Harwood K, Shea H, Viskochil D, Hirano P, Yen K, Ballal S, Huang M, Cowen NM, Bhatnagar A, Gevers E.   +26 more
europepmc   +1 more source